Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

BRCA1/2 test results impact risk management attitudes, intentions, and uptake.

O'Neill SC, Valdimarsdottir HB, Demarco TA, Peshkin BN, Graves KD, Brown K, Hurley KE, Isaacs C, Hecker S, Schwartz MD.

Breast Cancer Res Treat. 2010 Dec;124(3):755-64. doi: 10.1007/s10549-010-0881-4. Epub 2010 Apr 10.

2.

Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.

Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, Wood M, McKinnon W, Garber J, McCormick SR, Jandorf L, Schwartz MD.

Psychooncology. 2015 Jan;24(1):33-9. doi: 10.1002/pon.3560. Epub 2014 May 17.

3.

Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.

Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.

Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.

4.

Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy.

Howard AF, Bottorff JL, Balneaves LG, Kim-Sing C.

BMC Womens Health. 2010 Aug 5;10:24. doi: 10.1186/1472-6874-10-24.

5.

Risk-reduction surgery decisions in high-risk women seen for genetic counseling.

Ray JA, Loescher LJ, Brewer M.

J Genet Couns. 2005 Dec;14(6):473-84.

PMID:
16388328
6.

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.

Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Blum JL, Domchek SM, Chen J, Rebbeck TR.

Breast Cancer Res Treat. 2014 Nov;148(2):397-406. doi: 10.1007/s10549-014-3134-0. Epub 2014 Oct 14.

7.

Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.

Bluman LG, Rimer BK, Regan Sterba K, Lancaster J, Clark S, Borstelmann N, Iglehart JD, Winer EP.

Psychooncology. 2003 Jul-Aug;12(5):410-27.

PMID:
12833555
8.

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA.

JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.

PMID:
26181175
9.

BRCA1/2 testing in hereditary breast and ovarian cancer families III: risk perception and screening.

McInerney-Leo A, Hadley D, Kase RG, Giambarresi TR, Struewing JP, Biesecker BB.

Am J Med Genet A. 2006 Oct 15;140(20):2198-206.

PMID:
16969872
10.

Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice.

Graves KD, Vegella P, Poggi EA, Peshkin BN, Tong A, Isaacs C, Finch C, Kelly S, Taylor KL, Luta G, Schwartz MD.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):445-55. doi: 10.1158/1055-9965.EPI-11-0991. Epub 2012 Feb 10.

11.

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.

Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N.

Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.

12.

Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.

Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O.

Am J Obstet Gynecol. 2013 Apr;208(4):329.e1-6. doi: 10.1016/j.ajog.2013.01.026. Epub 2013 Jan 17.

PMID:
23333547
13.

Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results.

Rini C, O'Neill SC, Valdimarsdottir H, Goldsmith RE, Jandorf L, Brown K, DeMarco TA, Peshkin BN, Schwartz MD.

Health Psychol. 2009 Sep;28(5):569-78. doi: 10.1037/a0015205.

14.

The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.

van der Aa JE, Hoogendam JP, Butter ES, Ausems MG, Verheijen RH, Zweemer RP.

Fam Cancer. 2015 Dec;14(4):539-44. doi: 10.1007/s10689-015-9827-7.

15.

Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.

Julian-Reynier C, Mancini J, Mouret-Fourme E, Gauthier-Villars M, Bonadona V, Berthet P, Fricker JP, Caron O, Luporsi E, Nogu├Ęs C.

Eur J Hum Genet. 2011 May;19(5):500-6. doi: 10.1038/ejhg.2010.241. Epub 2011 Jan 26.

16.

BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.

McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP.

Am J Med Genet A. 2005 Mar 1;133A(2):165-9.

PMID:
15633195
17.

A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.

Sigal BM, Munoz DF, Kurian AW, Plevritis SK.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77. doi: 10.1158/1055-9965.EPI-12-0149. Epub 2012 May 3.

18.

BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.

McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP.

Am J Med Genet A. 2004 Oct 15;130A(3):221-7.

PMID:
15378542
19.

Psychological impact of receiving a BRCA1/BRCA2 test result.

Lodder L, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, van der Meer CA, van den Ouweland AM, Niermeijer MF.

Am J Med Genet. 2001 Jan 1;98(1):15-24.

PMID:
11426450
20.

Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing.

van Driel CM, Eltahir Y, de Vries J, Jaspers JP, Oosterwijk JC, Mourits MJ, de Bock GH.

Maturitas. 2014 Feb;77(2):180-4. doi: 10.1016/j.maturitas.2013.10.017. Epub 2013 Nov 1.

PMID:
24268650

Supplemental Content

Support Center